On December 19, Glonghui reported that the discount Weight Loss Drugs stock Hims & HERS fell 13% in Pre-Market Trading. Previously, the USA Food and Drug Administration (FDA) stated that the supply shortage of the Eli Lilly and Co Weight Loss Drugs injectable Tirzepatide has been addressed.
平价减肥药概念股Hims & Hers美股盘前跌13%
The affordable Weight Loss Drugs concept stock Hims & HERS fell 13% in Pre-Market Trading.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated